Ultragenyx
Stories
-
Ultragenyx posts results of Phase 3 DTX401 trial in Glycogen Storage Disease Type Ia
The study enrolled 52 participants and completed primary data collection on February 20, 2024. It evaluated DTX401's ability to reduce or eliminate dependence on exogenous glucose replacement therapy and to improve glucose control quality.